Biocon Biologics inks pact to provide cancer biosimilars to 30 countries in Africa, Asia
Bengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has recently signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).
The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs).
Biocon Biologics' R&D and manufacturing capabilities have enabled the Company to offer affordable biologics such as bTrastuzumab and bPegfilgrastim to cancer patients in developed markets like the European Union (EU) and the United States (U.S.). Biocon Biologics aims to deliver substantial savings to healthcare systems by enhancing access and availability of these high-quality, affordable biosimilar cancer therapies in 25 countries in Africa and 5 countries in Asia currently covered under CAP, led by CHAI. Biocon Biologics will initially supply bTrastuzumab and bPegfilgrastim and will expand the arrangement to include other biosimilars.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.